Home › Prostate Cancer › Maryland
Prostate Cancer clinical trials in Maryland
69 studies for Prostate Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Nov 13, 2026 · NCT07574541Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Suburban Hospital, Bethesda
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 13, 2026 · NCT04423211Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 13, 2026 · NCT07667400Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT05691465Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- National Institutes of Health Clinical Center, Bethesda
- FMH James M Stockman Cancer Institute, Frederick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT05588128Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Anne Arundel Urology, Annapolis
Recruiting
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT06511141Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · Men · Updated Nov 12, 2026 · NCT01834001Collection of Blood From Patients With Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT00923221Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT02594202Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Nov 10, 2026 · NCT06161506Collection of Blood From Patients With Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT00034216Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT00451022The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898WATER IV PCa (AS Sub-study)
- Johns Hopkins University, Baltimore
Recruiting
Ages 45 and older · Men · Updated Nov 6, 2026 · NCT07650448Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe
- Johns Hopkins Hospital, Baltimore
RecruitingPhase 1
Ages 40 to 75 · Men · Updated Nov 6, 2026 · NCT07271017Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 5, 2026 · NCT07745361Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- and 10 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- UM Upper Chesapeake Medical Center, Bel Air
- and 3 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07200830The COSMYC Trial (COmbined Suppression of MYC)
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · Men · Updated Oct 30, 2026 · NCT06922318A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Greenebaum Comprehensive Cancer Center ( Site 0021), Baltimore
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 30, 2026 · NCT06925737Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Oct 29, 2026 · NCT05519449Exercise in Prostate Cancer
- Johns Hopkins University, Baltimore
Recruiting
Ages 18 and older · Men · Updated Oct 29, 2026 · NCT06165302A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 110 · Men · Updated Oct 29, 2026 · NCT04633252Precision-Based Genomics in Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · Men · Updated Oct 26, 2026 · NCT04706663A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
- Maryland Oncology Hematology, PA, Rockville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Veterans Administration Medical Center-Baltimore, Baltimore
- and 7 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 23, 2026 · NCT05946213Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
- Johns Hopkins University, Baltimore
RecruitingObservational study
Ages 18 and older · Men · Updated Oct 22, 2026 · NCT04489719A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore
- Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore
- Chesapeake Urology ( Site 0009), Towson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06136650A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
- Johns Hopkins Hospital Sidney Kimmell Comprehensive Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 20, 2026 · NCT07213674A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · Men · Updated Oct 20, 2026 · NCT05361798Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 and older · All sexes · Updated Oct 16, 2026 · NCT01441089Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Oct 16, 2026 · NCT06096870Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · Men · Updated Oct 16, 2026 · NCT05616650Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Recruiting
Ages 18 and older · Men · Updated Oct 16, 2026 · NCT04692675Men at High Genetic Risk for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 30 to 75 · Men · Updated Oct 16, 2026 · NCT03805919Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · Men · Updated Oct 16, 2026 · NCT03354416Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Towson
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 15, 2026 · NCT07711002Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Johns Hopkins Hospital, Baltimore
RecruitingPhase 3
Ages 18 to 100 · Men · Updated Oct 15, 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Towson
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 14, 2026 · NCT06952803From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.